Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function

Darren K McGuire, Shuaib M Abdullah, Raphael See, Peter G. Snell, Jonathan McGavock, Lidia S. Szczepaniak, Colby R. Ayers, Mark H Drazner, Amit Khera, James A de Lemos

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

AimsTo assess the effect of rosiglitazone on cardiovascular performance and cardiac function. Methods and resultsOne hundred and fifty type 2 diabetes patients with cardiovascular disease (CVD) or ≥1 other CVD risk factor were randomized to receive rosiglitazone vs. placebo for 6 months. The primary outcome was peak oxygen uptake indexed to fat-free mass (VO2peak-FFM) during maximum exercise. A subset of 102 subjects underwent cardiac magnetic resonance imaging (cMRI). On hundred and eight subjects completed the study, including 75 completing the cMRI substudy. No significant differences were observed in mean VO2peak-FFM between rosiglitazone and placebo (26.1 ± 7.0 vs. 27.6 ± 6.6 mL/kg-FFM/min; P = 0.26). Compared with placebo, the rosiglitazone group had lower hematocrit (38 vs. 41; P < 0.001) and more peripheral oedema (53.7 vs. 33.3; P = 0.03). In the cMRI substudy, compared with placebo, the rosiglitazone group had larger end-diastolic volume (128.1 vs. 112.0 mL; P = 0.01) and stroke volume (83.7 vs. 72.9 mL; P = 0.01), and a trend toward increased peak ventricular filling rate (79.4 vs. 60.5; P = 0.07). ConclusionRosiglitazone increased peripheral oedema but had no pernicious effects on cardiovascular performance or cardiac function, with modest improvement in selected cMRI measures. Changes in indirect markers of plasma volume suggest expansion with rosiglitazone.

Original languageEnglish (US)
Pages (from-to)2262-2270
Number of pages9
JournalEuropean heart journal
Volume31
Issue number18
DOIs
StatePublished - Sep 2010

Keywords

  • Diabetes mellitus
  • Drugs
  • Exercise
  • Heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function'. Together they form a unique fingerprint.

Cite this